In the present study, we showed that activation of human CD4 T cells can be induced by anti-CD3 and collagen in a serum-free system . This activation was inhibited by the addition ofpeptides containing the RGD or Gly-Pro-X sequences . Significantly, we demonstrated that both the 1177 (CD26) structure and the VLA integrin family, particularly the VLA 3 complex, contribute to the functional interaction between collagen and CD4 cells since anti-1177 and antiVLA3 specifically inhibited this collagen-induced CD4 cell activation. Biochemical studies showed that the 1177 structure is not a member of the VLA integrin family. These results thus indicated that two different families of antigens serve as functional collagen receptors for CD4 T cell activation.
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indingof mAbs specific for the CD3/TCR complex can activate human T cells and lead to the biological expression of the T cell functional program (1) . However, while recent studies have shown that such receptors for extracellular matrix proteins as members of the integrin family (2, 3) may play important roles in cellular adhesion and migration, their role in immune response has yet to be clearly established . Another structure with unknown immunologic role that is also involved in cellular adhesion to extracellular matrix proteins is dipeptidyl peptidase IV (DPPIV). Found on a number of tissue types, DPPIV (CD26) is a membraneassociated intrinsic ectoenzyme that has a binding affinity for collagen (4) (5) (6) . We have recently developed a mAb called anti-1177, which recognizes the CD26 antigen on the surface of a subset of human T lymphocytes (7, 8) . We previously showed that fibronectin can synergize with anti-CD3 to promote CD4 cell proliferation in a serum-free culture system (9) . In the present study, we extended our studies of the role of extracellular matrix proteins in human T cell function by focusing on the interaction between collagen and its receptors in CD4 T cell activation.
Materials and Methods
Cells and Reagents. Highly purified human CD4 T cells were obtained as described previously (8, 9) . Collagen I, III, and IV, and BSA were from Sigma Chemical Co., St. Louis, MO. Laminin was from Collaborative Research, Bedford, MA. Antibodies reactive against T cell surface antigens used in this paper were described previously (7) (8) (9) . AntiVLA2 (12171) was obtained from Drs . K. Pischel and V Woods, University ofCalifornia, San Diego ; anti-UCHL1 was from Dr. P. Beverley, Imperial Cancer Research Fund, United Kingdom; antiVLA-5 (mAb 16) from Dr. K. Yamada, National Institutes of Health, Bethesda, MD. Anti-VLA-3 Q143), a gift from Dr. A. Albino, Memorial Sloan-Kettering Cancer Center (New York, NY), was in ascites form and was extensively dialyzed against PBS before experimentation. Peptides containing the GlyPro-X sequences were from Sigma Chemical Co. RGD-containing peptides were from Telios Pharmaceuticals, San Diego, CA.
Proliferation Assays. Proliferation assays were done as described earlier (9) . For inhibition studies, cells were incubated with all tested antibodies or peptides for 30 min in 37°C before culture and then placed in 96-well plates for proliferation assay. Data are expressed as mean of triplicate samples and are representative of three separate experiments. Each standard error was <15%. ['H]Thymidine incorporation for cells incubated with collagen alone was <500 cpm .
Biochemical Analyses. For Fig . 3 a, T lymphocytes were stimulated with PHA (0.25 Ag/ml) and rI1r2 (40 U/ml) (Biogen, Cambridge, MA) for 10 d, while for Fig. 3 b, resting CD4 cells were used after being prepared as described earlier. Biochemical analyses were then done as described previously (7, 9) . All samples were analyzed under reducing conditions.
Results and Discussion
Inhibition ofAnti-CD3 plus Collagen-induced Human CD4 T Cell Activation by Anti-1177 and Anti-4B4 (CD29) mAbs. As shown in Fig. 1 a, when combined with anti-CD3 antibody (0.1 ug/ml), collagen types I, 111, and IV could elicit CD4 cell proliferation, with collagen type I being most synergistic, while anti-CD3 or collagen alone cannot elicit such activation. We then examined whether the interaction of collagen with an integrin receptor or other class(es) of molecule on Plus collagen-induced proliferation by anti-1177 and anti-4134 . Addition of anti-1177 or anti-4134 at culture initiation inhibited proliferation of CD4 cells incubated in a serum free culture system in the presence of anti-CD3 (0 .1 ug/ml) and type I collagen (2 14g/ml) . (c) Inhibition of anti-CD3 plus collagen-induced proliferation by antiVLA-3 but not antiVLA-2 . Addition of antiVLA-3 but not antiVLA-2 antibodies at culture initiation inhibited proliferation of CD4 cells incubated in a serum-free culture system in the presence of anti-CD3 (0 .1 Wg/ml) and type I collagen (2 t~g/ml) .
CD4 cells was required for the observed cell activation . Since anti-4134 (CD29) antibody (10) reacts with the common /3 subunit associated with several ci subunits of the VLA integrin family, we undertook experiments to determine whether anti-4134 and antibodies recognizing other surface structures could modulate the activation of CD4 cells . In Fig. 1 b, addition of anti-4134 as well as anti-1177, but not control antibodies, at culture initiation could markedly inhibit the anti-CD3 plus type I collagen-induced CD4 cell proliferation, although the inhibitory effect of anti-1177 was slightly less than that of anti-4134 in most donors tested . In addition, incubation with antiTal antibody, which recognized the similar structure (CD26) defined by anti-1177 (7), showed virtually no inhibition of this CD4 cell activation, although some moderate inhibition was occasionally observed when higher antiTal antibody concentrations (>10 jAg/ml) were used (data not shown) . Since the VLA 2 and VLA3 molecules of the VLA integrin family have been proposed to be collagen receptors (3), we next determined which members of the VLA family are actually involved in the synergistic activation of CD4 cells by anti-CD3 and collagen type I . In Fig . 1 c, addition of antiVLA-3 and anti-4134 at culture initiation could inhibit CD4 cell proliferation in the presence of anti-CD3 and collagen type I in a dose-dependent fashion . AntiVLA3 and anti-1177 did not inhibit CD4 cell activation in the pres- 650 1177 and CD29 in Collagen-induced CD 4 T Cell Activation ence of CD3 plus fibronectin while, as previously described (9), both antiVLA-5 and anti-4134 inhibited CD4 cell activation by anti-CD3 plus fibronectin (data not shown) . Together, these results suggested that both VLA-3 and 1177 are of key importance in human CD4 lymphocyte activation induced by anti-CD3 plus collagen . It is still possible that while the particular antiVLA-2 antibody used in these experiments did not inhibit this collagen-induced activation, other anti-VLA-2 antibodies recognizing different epitopes may have an inhibitory effect. Due perhaps to the general nature of the low-affinity binding between collagen and its receptors (11, 12) , interactions of collagen with both VLA-3 and 1177 may be required for collagen-induced activation, and disruption of collagen binding to either VLA3 or 1177 by the addition of the respective antibodies results in virtually complete inhibition of the functional response of CD4 cells to collagen . Inhibition of Anti-CD3 plus Collagen-induced CD4 T Cell Activation by Peptides Containing RGD or GlyProX Sequences. Many of the integrin receptors recognize sites that include the tripeptide Arg-GlyAsp (RGD), a sequence that is common to many extracellular matrix proteins, including collagen, and which is thought to play a key role in cell adhesion and spreading (2, 13, 14) . As shown in Fig . 2 a, when the hexapeptide Gly-Arg-Gly-Asp-Ser-Pro (GRGDSP) containing the RGD sequence was added to cell cultures, proliferation of CD4 cells in response to anti-CD3 plus type I collagen was inhibited in a dose-dependent fashion . In contrast, no inhibition was observed with the related control hexapeptides GRGESP and GRADSP. The central structure of collagen can be regarded as being composed of repeating tripeptides with the general structure Gly-XY where X is preferentially proline and Y is preferentially 4-hydroxyproline (15) , and peptides containing this sequence have been shown to be involved in collagen-induced cell adhesion (5, 6, 12) . As shown in Fig .  2 b, this CD4 cell activation was also inhibited by the addi- tion of G1yProAla, G1yProGlyGly, and GlyProOHPro, but not GIyGlyGly and G1yG1yVa1 . Significantly, the addition of peptides containing the GlyProX sequences does not inhibit CD4 cell activation in the presence of fibronectin and anti-CD3, while the addition of peptides containing the RGD sequence does not inhibit CD4 cell proliferation induced by anti-CD3 plus PMA or anti-CD3 plus ID2 (data not shown) . Together, the above results suggested that peptides that include the RGD and G1yProX sequences contain important sites for the interaction of collagen with CD4 lymphocytes . The IF7 Molecule and VLA Integrin Family Belong to Distinct Families of Structures. In view of the inhibitory effects on cell-collagen interaction exhibited by antibodies recognizing the 1F7 structure and the VLA integrin family, structural comparison of 1F7 and the VLA integrin family was done by SDS-PAGE . From lysates of PHA stimulated T cells, anti-1F7 antibody precipitated the diffuse single band of the 110-kD glycoprotein, and anti-4B4 precipitated the diffuse band of 130--135-, the 165-, and 185-kD glycoproteins, as previously described (7, 9) . Anti-VLA2 and anti-VLA3 antibodies precipitated the 130-plus 165-kD and the 130-plus 135-kD glycoproteins, respectively (Fig. 3 a) . Since it is still possible that cell surface structures may be altered after T cell activation, we then performed sequential immunoprecipitation using lysates from resting CD4 T cells to exclude this possibility. Data from these studies showed that there was no crossreaction between anti-1F7 and anti-4B4 antibodies (Fig. 3 b) . The above results thus indicated that the 1F7 molecule and VLA integrin family belong to distinct families of structures.
In this paper we thus demonstrated that the 1F7 molecule and the VLA integrin family are functional collagen receptors on human CD4 cells . Anti-1F7, as well as anti-4B4, also prevented the adhesion and spreading of mesothelioma cells on plastic wells coated with collagen (data not shown) . It is important to note that anti-IF7 recognizes the CD26 an- tigen, which includes the structure recognized by antiTat and anti-DPPIV antibodies . Recently, Hanski et al. demonstrated that rat liver DPPIV has a binding affinity for collagen (6) , while Bauvois reported that mouse fibroblast DPPIV may be a collagen-binding protein (5) . While further studies are required to determine whether 1F7 and VLA-3 are two independent collagen receptors on human CD4 T cells or whether either molecule serves as an accessory molecule that facilitates collagen binding to its receptor, the identification of the 1F7 antigen as a functional collagen receptor, one distinct from the VLA integrin family, suggests the existence of distinct classes of functional collagen receptors that mediate collagen-dependent T cell function.
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